Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients
Brief Summary: This study examines the safety and efficacy of calcium channel blocker (CCB) in the treatment of hypertension of Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients. Angiotensin receptor blocker (ARB) was shown to have kidney protecting effects in patients with renal diseases including ADPKD, glomerulonephritis and diabetic nephropathy. In case whose blood pressure is not normalized by ARB alone, CCB is selected additionally. Recent research suggests genetic calcium channel disorder is responsible for the progression of ADPKD. It is not examined clinically if CCB treatment has any harmful effect to patients with ADPKD. This study examines the safety of Cilnidipine (CCB) in the ADPKD patients whose blood pressure is not controlled under 130/85 mmHg by Candesartan (ARB) alone.


Options:
A: Arm Label: ACE-I + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Placebo | Arm Label: ACE-I + ARB; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Telmisartan | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): ACE-I + ARB, ACE-I + placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): ACE-I + ARB | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): ACE-I + placebo
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Candesartan | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Candesartan and Cilnidipine | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Candesartan plus non-CCB agents | Intervention Type: DRUG; Name: Candesartan; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Candesartan and Cilnidipine; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Candesartan plus non-CCB agents; Assigned to Arm(s): C
C: Arm Label: Tolvaptan; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Study A, Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Telmisartan, Other: Standard Blood Pressure Control | Arm Label: Study A, Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Telmisartan, Other: Low Blood Pressure Control | Arm Label: Study A, Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Placebo, Other: Standard Blood Pressure Control | Arm Label: Study A, Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Placebo, Other: Low Blood Pressure Control | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): Study A, Arm 1, Study A, Arm 2, Study A, Arm 3, Study A, Arm 4 | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Study A, Arm 1, Study A, Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study A, Arm 3, Study A, Arm 4 | Intervention Type: OTHER; Name: Standard Blood Pressure Control; Assigned to Arm(s): Study A, Arm 1, Study A, Arm 3 | Intervention Type: OTHER; Name: Low Blood Pressure Control; Assigned to Arm(s): Study A, Arm 2, Study A, Arm 4

Answer: B